For Prostate Cancer with Bone Metastases, Denosumab Prevents Skeletal Complications

Share this content:

the Cancer Therapy Advisor take:

Denosumab reduces risk of skeletal complications compared to zoledronic acid in patients with castration-resistant prostate cancer (CRPC) and bone metastases, according to a study published in Annals of Oncology.

Researchers led by Matthew Smith, MD, PhD, of the Massachusetts General Hospital, observed results from a phase 3 trial in order to reassess the efficacy of denosumab using symptomatic skeletal events (SSE) as the endpoint. Patients who had CRPC, were not previously exposed to bisphophonates and had radiographic evidence of bone metastasis were randomized to either denosumab 120 mg plus intravenous (IV) placebo every four weeks, or IV zoledronic acid 4 mg plus placebo every four weeks.

They found that patients with CRPC that were treated with denosumab were at a significantly reduced risk of developing first SSE, and first and subsequent SSEs, compared to those who were on zoledronic acid.

In patients who had no-to-mild pain at baseline, both SSEs and skeletal-related events (SREs) were associated with moderate-to-severe pain development. When defined as SSE versus SRE, fewer patients had skeletal complications – fractures in particular.

Less Frequent Zoledronic Acid for Bone Metastases Safe, Effective
Denosumab reduces risk of skeletal complications compared to zoledronic acid in patients with castration-resistant prostate cancer.
This study reassessed the efficacy of denosumab using symptomatic skeletal events (SSEs) as a prespecified exploratory end point. In patients with CRPC and bone metastases, denosumab reduced the risk of skeletal complications versus zoledronic acid regardless of whether the end point was defined as SSE or SRE.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs